Mitophagy and heart failure
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605543348 | ||
| 003 | CHVBK | ||
| 005 | 20210128100926.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150301xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s00109-015-1254-6 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s00109-015-1254-6 | ||
| 245 | 0 | 0 | |a Mitophagy and heart failure |h [Elektronische Daten] |c [Sarah Shires, Åsa Gustafsson] |
| 520 | 3 | |a Cardiac mitochondria are responsible for generating energy in the form of ATP through oxidative phosphorylation and are crucial for cardiac function. Mitochondrial dysfunction is a major contributor to loss of myocytes and development of heart failure. Myocytes have quality control mechanisms in place to ensure a network of functional mitochondria. Damaged mitochondria are degraded by a process called mitochondrial autophagy, or mitophagy, where the organelle is engulfed by an autophagosome and subsequently delivered to a lysosome for degradation. Evidence suggests that mitophagy is important for cellular homeostasis, and reduced mitophagy leads to inadequate removal of dysfunctional mitochondria. In this review, we discuss the regulation of mitophagy and the emerging evidence of the cardioprotective role of mitophagy. We also address the prospect of therapeutically targeting mitophagy to treat patients with cardiovascular disease. | |
| 540 | |a Springer-Verlag Berlin Heidelberg, 2015 | ||
| 690 | 7 | |a Mitophagy |2 nationallicence | |
| 690 | 7 | |a Heart failure |2 nationallicence | |
| 690 | 7 | |a Autophagy |2 nationallicence | |
| 690 | 7 | |a Mitochondria |2 nationallicence | |
| 700 | 1 | |a Shires |D Sarah |u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive MC 0758, 92093-0758, La Jolla, CA, USA |4 aut | |
| 700 | 1 | |a Gustafsson |D Åsa |u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive MC 0758, 92093-0758, La Jolla, CA, USA |4 aut | |
| 773 | 0 | |t Journal of Molecular Medicine |d Springer Berlin Heidelberg |g 93/3(2015-03-01), 253-262 |x 0946-2716 |q 93:3<253 |1 2015 |2 93 |o 109 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00109-015-1254-6 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a review-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s00109-015-1254-6 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Shires |D Sarah |u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive MC 0758, 92093-0758, La Jolla, CA, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Gustafsson |D Åsa |u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive MC 0758, 92093-0758, La Jolla, CA, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Journal of Molecular Medicine |d Springer Berlin Heidelberg |g 93/3(2015-03-01), 253-262 |x 0946-2716 |q 93:3<253 |1 2015 |2 93 |o 109 | ||